Company intelligence / Profile preview
NeuroBo Pharmaceuticals
- Ownership
- Public · NRBO
- Development stage
- Other
Overview
NeuroBo Pharmaceuticals—now rebranding to MetaVia—is a clinical-stage biotech focused on cardiometabolic diseases. Its lead programs are DA‑1241, a GPR119 agonist in Phase IIa trials for MASH/NASH with promising interim results expected by mid-to-late 2024, and DA‑1726, an oxyntomodulin analogue dual agonist targeting GLP1R/GCGR currently in early clinical development for obesity. The company has shifted away from its original focus on neurodegenerative diseases following its merger with Gemphire Therapeutics. It has strategic partnerships with Dong-A ST and ImmunoForge to advance its pipeline using innovative drug delivery platforms.
- Therapeutic areas
- EndocrinologyNeurologyMetabolic Disorders
- Modalities
- Small molecules (e.g., DA‑1241)Peptides/biologics (e.g., DA‑1726, an oxyntomodulin analogue)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on NeuroBo Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroBo Pharmaceuticals.